Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


22 Items
Title  Creator  Group name  Publishing year 
PTPN13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells Aptecar et al. EquipeMY 2023-10-21
Mechanical signatures of human colon cancers Lopez-Crapez et al. EquipeJC 2022-07-21
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial Ychou et al. EquipeMY 2022-05
Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer Bobrie et al. EquipeNB 2022-10-03
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1) Assenat et al. EquipeMY 2021-02-01
FTO-mediated cytoplasmic m6Am demethylation adjusts stem-like properties in colorectal cancer cell Relier et al. EquipeCTCS 2021-03-19
Clinicopathological Correlates of ?? T Cell Infiltration in Triple-Negative Breast Cancer Boissière-Michot et al. EquipeCTCS 2021-02-12
A Truncated NRIP1 Mutant Amplifies Microsatellite Instability of Colorectal Cancer by Regulating MSH2/MSH6 Expression, and Is a Prognostic Marker of Stage III Tumors Palassin et al. EquipeMY 2021
Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27) Samalin et al. EquipeMY May 15, 2020
Identification of a regulatory V?1 gamma delta T cell subpopulation expressing CD73 in human breast cancer Chabab et al. EquipeCTCS 2020-06
Diversity of Tumor-Infiltrating, ?? T-Cell Abundance in Solid Cancers Chabab et al. EquipeNB Jun 24, 2020
Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer Jacot et al. EquipeELC 2020-08-01
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer Jacot et al. EquipeMY 2020-03-30
The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases Darlix et al. EquipeCTCS Jan 30, 2019
Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples Ho-Pun-Cheung et al. EquipeCTCS Dec 03, 2019
Correction: The p53 isoform delta133p53ß regulates cancer cell apoptosis in a RhoB-dependent manner Arsic et al. EquipeMY 2017
TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast cancer cell invasion Chevalier et al. EquipeMY Feb 22, 2016
Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases? Darlix et al. EquipeCTCS 11 15, 2016
Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients Darlix et al. EquipeCTCS 07 07, 2016
Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas Boissière-Michot et al. EquipeMY Aug 2016
High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers Jacot et al. EquipeMY Dec 18, 2015
Evaluation of the dimerization profiles of HER tyrosine kinases by time-resolved Förster resonance energy transfer (TR-FRET) Lopez-Crapez et al. EquipeMY 2015
22 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés